drugset / Trial / NCT00992862

A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

NCT00992862

Phase 1 Completed 60 enrolled Paddock Laboratories, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Moexipril Small molecule 15 mg Oral

Indications

No indication recorded.